GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19

The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE trial.